Update on treatment recommendations from the Third International Workshop on Waldenstrom's macroglobulinemia. - Wikidata - wikimedia - TriplyDB

Update on treatment recommendations from the Third International Workshop on Waldenstrom's macroglobulinemia.

Update on treatment recommendations from the Third International Workshop on Waldenstrom's macroglobulinemia.

http://www.wikidata.org/entity/Q46892996

about

The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines Thalidomide and rituximab in Waldenstrom macroglobulinemia Review of clinical trials conducted in Waldenstrom macroglobulinemia and recommendations for reporting clinical trial responses in these patients Long-term survival in Waldenstrom macroglobulinemia: 10-year follow-up of Southwest Oncology Group-directed intergroup trial S9003.Update on therapeutic options in Waldenström macroglobulinemia Statins impair antitumor effects of rituximab by inducing conformational changes of CD20 Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom Macroglobulinemia.Otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR(™) therapeutic protein, for relapsed or refractory NHL patients.Evolution of Management and Outcomes in Waldenström Macroglobulinemia: A Population-Based Analysis.Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia.Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180.Waldenstrom macroglobulinemia Novel therapeutic agents in Waldenström's macroglobulinemia.Therapy-Related Myeloid Neoplasms in Chronic Lymphocytic Leukemia and Waldenstrom's Macroglobulinemia New Therapeutic Approaches for Waldenstrom Macroglobulinemia Novel agents in Waldenström macroglobulinemia.An Autopsy Case of Amyotrophic Lateral Sclerosis with Waldenström Macroglobulinemia and Anti-MAG Gammopathy Simultaneous occurrence of fibrillary glomerulonephritis and renal lesions in nonmalignant monoclonal IgM gammopathy Novel agents in Waldenstrom Macroglobulinemia.Clinical value of minor responses after 4 doses of rituximab in Waldenström macroglobulinaemia: a follow-up of the Eastern Cooperative Oncology Group E3A98 trial.Dual targeting of the proteasome regulates survival and homing in Waldenstrom macroglobulinemia Treatment of plasma cell dyscrasias with lenalidomide.CDDO-imidazolide mediated inhibition of malignant cell growth in Waldenström macroglobulinemia Novel treatment regimens for Waldenström's macroglobulinemia.Current options to manage Waldenström's macroglobulinemia.Immunoglobulin M 'Flare' Seen in a Case of Waldenstrom's Macroglobulinemia: Successfully Managed by Therapeutic Plasma Exchange.Rituximab and fludarabine or cyclophosphamide combination treatment for older waldenström macroglobulinemia patients.Advances in the treatment of monoclonal gammopaties: The emerging role of targeted therapy in plasma cell dyscrasias.Retrospective analysis of prognostic factors for Waldenstrӧm macroglobulinemia: a multicenter cooperative study in Japan.Treatment Recommendations in Waldenström Macroglobulinemia

P2860

Q28244041-30E7B64D-6A2D-461B-8969-8A00A291D322 Q28290236-E449EF46-7176-4B65-90D5-F09201C345F4 Q28291293-93F40BF0-5530-417D-BB95-716799BE5D8A Q28291793-AA2DE23C-0848-47CE-AE4B-2AFE8ADE91DC Q28297940-848F86F7-14A4-4C8D-99A2-6D8C13544010 Q28304195-8F3C398A-7DC4-42AC-9597-B02996AA7FEB Q28472420-FAD363F1-AAB3-4DD7-ABFC-694C738DE1FC Q33382030-C2ABCE4E-159A-4306-8154-073980001009 Q33388196-81216651-4FE1-416B-95FB-A770B85C0CE7 Q33414529-3D5EA500-E882-4257-AB26-5ED06B759AE4 Q33417223-7C270792-C5EF-4096-BE62-05CFDC09F756 Q33434251-BD167CC4-AFE4-42ED-873F-D54B9CB81DB7 Q33711127-CC0F4A1A-BC36-492A-BC7D-1305DA5218E5 Q34106817-FF61FDC6-FC2D-4A2F-82CF-2391C8C3822F Q34608608-78D60B22-8E3D-4E88-8B27-041291A2E3A9 Q35097328-FBACDD68-A9C4-4711-A38E-E6FF92155C2A Q35097365-788C9E05-8F25-46F2-B810-F48507737702 Q35153656-E43F1F48-76C2-43FE-B480-4304ADE72010 Q35176177-4C2471AF-C832-4421-9955-34225D09B03E Q35429544-55AE61B1-6048-407A-BE2A-D92F8775A21B Q35649440-AD92E6E7-9EC5-42B1-A00F-84E5A743C95C Q35927848-0D4876B5-34C4-41AD-BC70-914D82574AFD Q36117791-EE5F6F97-006E-4B6F-B424-6002EA820241 Q36542990-46090F30-207A-4FA3-9079-5781778BBAC7 Q36591379-14B7885B-0BFE-4761-AEE1-8ED4213B3CDA Q37176044-4FD6A165-5DB0-4185-8224-8854EE3D5632 Q37418372-071E6438-DCD1-48D2-AC26-405B63D9E44E Q37810101-63A364BA-FB07-4535-95DE-B0C70CA4E7E8 Q39358109-35ED168C-6605-4006-8BCD-613F54DE2750 Q41970906-F69A0306-C10A-4926-A5DA-A4F1FAC8FDD9 Q42771773-4CCF03B9-1C2A-412E-BA48-CCBCC07AD4C6 Q43078127-8241DD4F-33C0-4AE7-92F5-3943317F2397 Q48158113-861BA8EF-DBDE-4880-B095-2E8806268C7F Q57904158-759F0290-E6D1-47FE-B9D1-D37D9D862B55

P2860

Update on treatment recommendations from the Third International Workshop on Waldenstrom's macroglobulinemia.

http://www.wikidata.org/entity/Q46892996

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年学术文章

@wuu

2006年学术文章

@zh

2006年学术文章

@zh-cn

2006年学术文章

@zh-hans

2006年学术文章

@zh-my

2006年学术文章

@zh-sg

2006年學術文章

@yue

2006年學術文章

@zh-hant

name

Update on treatment recommenda ...... ldenstrom's macroglobulinemia.

@en

Update on treatment recommenda ...... ldenstrom's macroglobulinemia.

@nl

type

label

Update on treatment recommenda ...... ldenstrom's macroglobulinemia.

@en

Update on treatment recommenda ...... ldenstrom's macroglobulinemia.

@nl

prefLabel

Update on treatment recommenda ...... ldenstrom's macroglobulinemia.

@en

Update on treatment recommenda ...... ldenstrom's macroglobulinemia.

@nl

P1433

Q46892996-04B028CA-CD55-4E9A-A3C5-6F3CEADBD4EC

P1476

Q46892996-70B7CA3D-FCAC-4EFC-8258-AB863F7480E5

P2093

Q46892996-24484CCD-9DC4-41C6-B595-620D1200B57B

Q46892996-4805DC49-F163-4275-A4EC-FD3689F12E92

Q46892996-4E1CAB2E-4A98-4D29-809F-C546E4F4D5B1

Q46892996-776BA9E7-8E68-4FCF-BCD2-AB45DF494F31

Q46892996-79E460F7-87EC-44D8-8E14-F0EE1CDDE679

Q46892996-8DA25B2E-B13F-48AC-B5AD-566268CAD75B

Q46892996-90CBCF43-F5B4-4964-913F-232CE5CFAB52

Q46892996-A13F3211-7A93-455C-96A0-5F5D36D549B6

Q46892996-BB53EADC-4DC0-4C05-9EA6-4D25ACD2CE02

Q46892996-DDFCC865-1340-49B7-AD52-3E110A7F24BF

P304

Q46892996-440A7FE7-EA7B-4F47-B6F2-1C417867FBC6

P31

Q46892996-FCCF53ED-F301-4425-95B0-9A9F1F0D92DB

P356

Q46892996-67EBB88C-B49A-460C-AB94-74E17F1006C1

P407

Q46892996-B87BAF17-F1B4-4FF1-9817-63E2C1E1CAA1

P433

Q46892996-5F62AC24-F46A-40CE-9F2D-5B00CCC1B1AD

P478

Q46892996-04DDA39E-15AC-46C9-BF2E-D794D48D027F

P50

Q46892996-37A1D0F8-73F7-4C2F-BD2E-4140CDA656D8

Q46892996-46FB8EE4-CBE0-47F3-992F-A0A3038C6A1E

Q46892996-542840BC-3A1C-4A40-9140-54B506E64C80

Q46892996-61CE399D-3821-400B-89BF-C6D591697AC7

Q46892996-8B40BD54-5E96-4446-9F5C-5074B96C707F

Q46892996-BC01AE80-4389-4852-894A-A3ECBE9E8D3D

Q46892996-D35561BD-AD34-4E18-9B54-26DACF323FD7

P577

Q46892996-FC117045-8D98-492F-9485-5D8874FC935F

P5875

Q46892996-6BFBC4E4-3FB4-4B67-A2E4-05ABAAA08662

P698

Q46892996-F106DAFD-BD80-4C64-8206-D503A17C678A

P921

Q46892996-FA033828-FAC2-478B-8627-74070FADDE43

P356

BLOOD-2005-02-0833

P1433

P1476

Update on treatment recommenda ...... ldenstrom's macroglobulinemia.

@en

P2093

Athanasios Anagnostopoulos

http://www.w3.org/2001/XMLSchema#string

Enrica Morra

http://www.w3.org/2001/XMLSchema#string

Eva Kimby

http://www.w3.org/2001/XMLSchema#string

Gwen Nichols

http://www.w3.org/2001/XMLSchema#string

Jean-Paul Fermand

http://www.w3.org/2001/XMLSchema#string

Joan Blade

http://www.w3.org/2001/XMLSchema#string

Marvin J Stone

http://www.w3.org/2001/XMLSchema#string

Pierre Morel

http://www.w3.org/2001/XMLSchema#string

Roger Owen

http://www.w3.org/2001/XMLSchema#string

Stephen Johnson

http://www.w3.org/2001/XMLSchema#string

P304

3442-3446

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2005-02-0833

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

107

http://www.w3.org/2001/XMLSchema#string

P50

David G. Maloney

Ramón García-Sanz

Giampaolo Merlini

Meletios A. Dimopoulos

Andrew Branagan

P577

2006-01-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7362597

http://www.w3.org/2001/XMLSchema#string

P698

16410453

http://www.w3.org/2001/XMLSchema#string

P921